The CEO of David Protein, renowned for its high-protein nutrition bars, made a public statement on X platform on Monday, revealing that Dr. Peter Attia, a well-known figure in longevity, has resigned from his position as Chief Science Officer at David.
The Story Unfolds
The recent announcement follows the emergence of over 1,700 documents, including emails, released last Friday in connection with the scandal involving convicted sex offender Jeffrey Epstein. Dr. Attia, a key figure in the food startup’s executive team and an early investor, found his name entangled in the controversy.
Dr. Peter Attia: A Brief Background
For those unfamiliar, Dr. Attia is a Canadian American physician celebrated for his expertise in longevity and preventive health. His book “Outlive: The Science and Art of Longevity” and his popular podcast have positioned him as a leading voice in the field. Recently joining CBS as a contributor, Dr. Attia has been instrumental in advocating for health optimization strategies.
David Protein’s Journey
Established three years ago in New York, David Protein secured a notable $75 million Series A funding round led by Greenoaks last year. With the successful launch of their flagship protein bar in 2024, boasting 28 grams of protein, zero sugar, and 150 calories, the company has seen substantial growth in the market.
Addressing Controversy
In a detailed post on X, Dr. Attia expressed regret over certain inappropriate content in his exchanges with Epstein. However, he clarified that he was not engaged in any criminal activities and had no involvement with Epstein’s illicit operations. Dr. Attia elaborated on his acquaintance with Epstein and the reasons for maintaining ties with him post his 2008 conviction.
The Ripple Effect
Beyond David Protein, implications of the scandal extend to Biograph, a healthcare testing and longevity startup co-founded by Dr. Attia and John Hering. The company appears to be distancing itself from Dr. Attia, with changes observed on its website omitting his name or displaying errors.
Biograph’s Evolution
Biograph emerged from stealth mode a year ago, backed by prominent investors like Vy Capital and Human Capital. Offering premium preventive health services at a subscription fee ranging from $7,500 to $15,000 annually, the company aims to redefine healthy aging standards. Dr. Attia, previously acknowledged as a co-founder, seems to be fading from the company’s public presence.
